Patent Application

App. No. 12/741,030

Abstract

Claims (12)

1 . A method for treating or preventing a disorder or disease associated with α1-AT deficiency in a subject, the method comprising administering, subcutaneously, a therapeutically or prophylactically effective amount of α1-AT to the subject.

2 . A method for treating or preventing a disorder or disease associated with α1-AT deficiency in a subject, the method comprising:

a) determining a therapeutically or prophylactically effective amount of α1-AT based on a dosing regimen comprising intravenously administered α1-AT; and

b) administering, subcutaneously, a dose of at least about 120% of the therapeutically or prophylactically effective amount of α1-AT to the subject.

3 . An α1-AT formulation suitable for subcutaneous administration.

4 . The formulation of claim 3 , wherein the formulation is a lyophilized formulation to be reconstituted prior to administration.

5 . A method for treating or preventing a disorder or disease associated with α1-AT deficiency in a subject, the method comprising administering, subcutaneously, a composition comprising a therapeutically or prophylactically effective amount of an α1-AT to the subject, wherein α1-AT is administered in combination with one or more reagents.

6 . The method of claim 5 , wherein the one or more reagents is a hyaluronidase.

7 . The method of claim 6 , wherein the composition is a pharmaceutical composition comprising α1-AT and a hyaluronidase, wherein the composition is suitable for subcutaneous administration to the subject.

8 . An article of manufacture comprising an α1-AT formulation for subcutaneous administration.

9 . The article of claim 8 further comprising a hyaluronidase.

10 . The article of claim 8 , wherein the formulation further comprises a hyaluronidase.

Assignments (29)